Open AI launches "GPT Store" with three million applications and ChatGPT Team for small businesses

  "Following the example of Apple's App Store, Open AI is also transforming into a platform. Developers can now offer their applications on the marketplace.

 

     Open AI has launched its marketplace for AI applications. In the “GPT Store” users can now upload and offer their own specialized AI applications. Three million "GPTs" have already been developed since last November, when Open AI announced the feature, and are now available at launch, divided into ten categories such as Writing, Productivity, Research & Analysis, Programming, Education and Lifestyle.

 

     This means that Open AI becomes a platform and follows the successful App Store model modeled on Apple. The iPhone only became a sales success after the introduction of the App Store, as the apps from external developers enhanced the product and justified the high price in the eyes of customers. When iPhone sales began, the App Store did not initially exist and sales were meager. Only later did sales explode to more than two billion devices to date.

 

     Open AI is now hoping that the platform model will have a similar effect and will soon allow developers to share in sales. Unlike in the App Store, the developers do not need to have any programming knowledge, but can specify the functions of their "GPTs" in the "Instructions". 

 

This means the barrier to entry for developers is very low.

 

     On the other side of the market, Open AI users can now access many more specialized functions and improve results. The first examples come from education, as suitable content can be provided with the GPTs. Consensus provides easy access to 200 million research reports, making them easier to search.

 

     Classic educational platforms like Chegg are already noticing the new competition, as many students use ChatGPT.

 

     ChatGPT Team for small businesses

 

     Another innovation that shows Open AI's ambitions in the mass market is ChatGPT Team. 

 

In addition to the enterprise solution for large companies, small companies or teams can now also develop their own models and feed them with their business data for little money. 

 

The data is not used to train the models.

 

 Open AI is thus responding to users' desire to create secure solutions for small and medium-sized companies. 

 

Usage costs $25 per user per month for annual billing and $30 for monthly billing." [1]

 

1. Open AI startet "GPT-Store" mit drei Millionen Anwendungen. Frankfurter Allgemeine Zeitung (online)  Frankfurter Allgemeine Zeitung GmbH. Jan 11, 2024. Von Holger Schmidt

Vokietijos biotechnologijos kompanijos surinko milijardą eurų per metus: asociacija mato tendencijų pasikeitimą / darbuotojų mažinimas ir nenoras investuoti išliks 2024 m.

  „Atrodo, kad užliūlis po Koronos bumo baigėsi: 2023 metais Vokietijos biotechnologijos pirmą kartą surinko daugiau pinigų iš investuotojų.

 

     Nepaisant sudėtingos padėties tarptautinėse finansų rinkose, Vokietijos biotechnologijų bendrovės pernai sugebėjo iš investuotojų pritraukti daugiau pinigų, nei užpernai.

 

     Pramonės asociacija „Bio Deutschland“ ketvirtadienį Berlyne paskelbė, kad buvo surinkta apie 1,08 mlrd. eurų kapitalo.

 

     Prieš metus tai siekė 920 milijonų eurų.

 

     2023 m. iš rizikos kapitalistų į privačias įmones plaukė 533 milijonai eurų, kiek daugiau, ty 547 milijonai, atiteko biržinėms biotechnologijų įmonėms kapitalo padidinimo forma, kaip matyti iš Bio Deutschland surinktų duomenų. Asociacija mano, kad farmacijos pramonei svarbaus tiekėjų sektoriaus finansavimas yra stabilus.

 

     Atsiranda tendencijų pasikeitimas

 

     Tačiau nuotaikos pramonėje išlieka prieštaringos. Asociacijos atliktoje įmonių narių apklausoje apie 29 proc. respondentų savo dabartinę verslo situaciją apibūdino, kaip blogą. 2022 metais taip teigė tik 13 proc. Priešingai, apie 35 procentai apklaustųjų tikisi geresnės verslo padėties 2024 m. nei 2023 m., žymiai daugiau, nei praėjusiais metais – 26 procentai. „Nuostabu, kad daugelis generalinių direktorių mano, kad padėtis toliau nepablogės ir net tendencija pasikeis“, – sako asociacijos vadovas Oliveris Schachtas. Tačiau jis taip pat mato iššūkius joo pramonėje.

 

     Po to, kai korona pandemija ir didelė Biontech mRNR vakcinos sėkmė suteikė vietos biotechnologijų pramonei didelį finansavimą ir visuomenės dėmesį, nuo 2022 m. viskas vėl tapo sunkiau. Šiuo metu pramonė net nebuvo surinkusi trečdalio finansavimo apimties, nei dvejais ankstesniais metais, kurie iki šiol buvo geriausi Vokietijos biotechnologijų pramonės finansavimo metai su maždaug 3 ir 2,3 mlrd. eurų kapitalo.

 

     Mažiau finansavimo raundų, bet kartais didesni

 

     Po bumo sekė nežinomybė. Finansavimo raundai tapo retesni, bet kai kuriais atvejais didesni.

 

     Biotechnologijų kompanijai ITM, kuri nori vėžį gydyti radioaktyviais vaistais, 2023 m. Ji užsitikrino 255 milijonus eurų naujo kapitalo – beveik pusę pinigų, kuriuos rizikos kapitalistai išdalijo pernai.

 

     Apskritai donorai išlieka atsargūs. Neigiama personalo planavimo ir investicijų į mokslinius tyrimus ir plėtrą (MTEP) tendencija išliks ir 2024 m.

 

     Tendencijos tyrimo duomenimis, šiemet darbo jėgą mažinti planuoja tris kartus daugiau respondentų, nei praėjusiais metais.

 

     Žmonių, norinčių padidinti savo etatų skaičių, skaičius išlieka stabilus – 45 proc. Tačiau planuojamas darbo jėgos mažinimas vis dar yra žemas, sakė Schachtas.

 

     Kalbant apie investicijas į mokslinius tyrimus ir plėtrą, 39 procentai apklaustųjų nori sulėtinti tempą, o prieš metus – 33 procentai. Atsižvelgiant į tai, kad biotechnologijų pramonė turi skatinti naujoves, kad būtų patraukli tolesniam finansavimui, IPO ar farmacijos įmonių įsigijimams, tai nėra geras signalas." [1]

1. Deutsche Biotechs sammeln eine Milliarde Euro ein: Verband sieht Trendwende / Personalabbau und Investitionszurückhaltung bleiben aber auch 2024 bestehen
Frankfurter Allgemeine Zeitung (online)Frankfurter Allgemeine Zeitung GmbH. Jan 11, 2024. Von Vanessa Trzewik

German biotechs raise one billion euros in one year: Association sees trend reversal / staff cuts and reluctance to invest will continue in 2024

"The lull after the Corona boom seems to be over: in 2023, German biotechs raised more money from investors for the first time.

 

     Despite the difficult situation on the international financial markets, German biotechnology companies were able to raise more money from investors last year than in the previous year.

 

     The Bio Deutschland industry association announced on Thursday in Berlin that around 1.08 billion euros in capital had been collected.

 

     A year earlier it was 920 million euros.

 

     In 2023, 533 million euros flowed from venture capitalists to private companies, a little more, namely 547 million, went to listed biotech companies in the form of capital increases, as can be seen from the data collection by Bio Deutschland. The association believes that the financing of the supplier sector, which is important for the pharmaceutical industry, is stable.

 

     Trend reversal is emerging

 

     However, the mood in the industry remains mixed. In a survey conducted by the association among its member companies, around 29 percent of respondents described their current business situation as bad. In 2022, only 13 percent said this. In contrast, around 35 percent of those surveyed expect a better business situation in 2024 than in 2023, significantly more than in the previous year with 26 percent. “It is remarkable that many managing directors assume that the situation will not worsen any further and that there will even be a trend reversal,” says association boss Oliver Schacht. But he also sees the challenges in his industry.

 

     After the corona pandemic and Biontech's great mRNA vaccine success gave the local biotech industry a strong boost in financing and public attention, things became more difficult again from 2022. At this point in time, the industry had not even raised a third of the financing volume of the two previous years, which had been the best financing years for the German biotech industry to date with around 3 and 2.3 billion euros in capital.

 

     Fewer financing rounds, but sometimes larger

 

     The boom was followed by uncertainty. The financing rounds became less frequent, but in some cases larger.

 

     The biotech company ITM, which wants to treat cancer with radioactive drugs, benefited from this in 2023. It secured 255 million euros in fresh capital, almost half of the money that venture capitalists distributed last year.

 

     Overall, donors remain cautious. The negative trend in personnel planning and investments in research and development (R&D) will continue in 2024.

 

     According to the trend survey, three times as many respondents are planning to reduce their workforce this year as in the previous year.

 

     The number of people who want to increase their staff remains stable at 45 percent. However, the planned workforce reductions are still at a low level, said Schacht.

 

     When it comes to R&D investments, however, 39 percent of those surveyed want to slow down, compared to 33 percent a year ago. Given that the biotech industry needs to drive innovation in order to be attractive for further financing, IPOs or acquisitions by pharmaceutical companies, this is not a good signal." [1]

 

1. Deutsche Biotechs sammeln eine Milliarde Euro ein: Verband sieht Trendwende / Personalabbau und Investitionszurückhaltung bleiben aber auch 2024 bestehen
Frankfurter Allgemeine Zeitung (online)Frankfurter Allgemeine Zeitung GmbH. Jan 11, 2024. Von Vanessa Trzewik